Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
VA Office of Research and Development
Replimune Inc.
GlaxoSmithKline
ImmunityBio, Inc.
AIO-Studien-gGmbH
M.D. Anderson Cancer Center